Clinical trials: Extensive Stage Lung Small Cell Carcinoma
Lung Cancer
Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy may be more effective in preventing brain metastases.
- Trial name
- NCT00006344
- Testing
- radiation therapy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Lung Cancer
Studying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) Region
RATIONALE: Gathering information about genetic and environmental factors from patients with lung cancer and their partners and first-degree relatives may help doctors learn more about the disease.
- Trial name
- NCT00693836
- Testing
- genetic linkage analysis, loss of heterozygosity analysis, mutation analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cancer Research Centre at Weston Park Hospital
Small Cell Lung Cancer Extensive Stage, Resistance to Immunotherapy
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
The phase II study enrolled ES-SCLC patients who had disease progression after anti-PD-1/L1 therapy. Participants received intravenous sintilimab 200 mg on day one and oral daily anlotinib 8-12 mg on days 1-14 once every three…
- Trial name
- NCT07022301
- Testing
- sintilimab combined with anlotinib
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Small Cell Lung Cancer Extensive Stage
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment…
- Trial name
- NCT06739928
- Testing
- Irinotecan liposome (II) combined with adebrelimab and carboplatin, etoposide combined with adebrelimab and carboplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT07070011
- Testing
- EC/EP + ICIs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Chest Hospital of Shanghai Jiao Tong University
Non Small Cell Lung Cancer, NSCLC
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Both metastatic squamous non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) are incurable with current therapies, but due to mutations induced by cigarette smoke, typically express a large number…
- Conditions
- Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer, Small Cell Lung Extensive Stage
- Trial name
- NCT03166254
- Testing
- Pembrolizumab, NEO-PV-01 vaccine, Biopsy
- Sponsor
- Washington University School of Medicine
Small Cell Lung Cancer
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
- Trial name
- NCT07376499
- Testing
- Liposome Irinotecan, Platinum, Anlotinib
- Volunteers
- 31 people
- Sponsor
- China Medical University, China
Small Cell Lung Cancer
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
This is a Phase II, single-arm, single-center study evaluating Chidamide combined with a PD-L1 inhibitor, carboplatin, and etoposide as first-line therapy in extensive-stage small-cell lung cancer (ES-SCLC) patients.
- Trial name
- NCT07373964
- Testing
- Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- China Medical University, China
Small Cell Lung Cancer Extensive Stage
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT06954246
- Testing
- MHB088C for Injection, Topotecan, Irinotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Respiratory Tract Neoplasms, Thoracic Neoplasms
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin/Cisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of…
- Conditions
- Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- NCT06177925
- Testing
- Adebrelimab, Carboplatin/Cisplatin, Etoposide
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Small Cell Lung Cancer
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
This Phase II study was designed to evaluate the safety and efficacy of albumin paclitaxel in combination with simvastatin compared with treatment with albumin paclitaxel alone in ES-SCLC patients relapsed from first-line…
- Trial name
- NCT04698941
- Testing
- Albumin Paclitaxel, Simvastatin
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Colorectal Cancer, Lung Cancer
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
RATIONALE: A disease management program may be more effective than standard therapy in improving quality of life and controlling symptoms in patients with cancer.
- Conditions
- Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00684801
- Testing
- questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 605 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
The purpose of this study was to evaluate the efficacy of low-dose radiotherapy (LDRT) combined with durvalumab, etoposide, and cisplatin/carboplatin in the first-line treatment of extensive-stage small cell lung cancer.
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab
- Trial name
- NCT05092412
- Testing
- Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- You Lu
Extensive Small Cell Lung Cancer
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
A randomized, double-blind, controlled, multicenter phase III study of TQB2450 or placebo combined with Anlotinib, etoposide and carboplatin versus Etoposide and Carboplatin in subjects with extensive small cell lung cancer.
- Trial name
- NCT04234607
- Testing
- TQB2450, Anlotinib, Etoposide
- Where
- 26 sites in China
- Volunteers
- 738 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Extensive-stage Small Cell Lung Cancer
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
The purpose of this study is to determine if a combination of investigational agents is safe to give to people with small cell lung cancer (SCLC) after standard chemotherapy has been attempted.
- Trial name
- NCT03085849
- Testing
- Durvalumab, Tremelimumab, SGI-110
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Catherine Shu
Small Cell Lung Carcinoma
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs.
- Trial name
- NCT00977561
- Testing
- figitumumab, Cisplatin (Or Carboplatin), Etoposide
- Where
- 51 sites in United States, Canada and 2 more
- Volunteers
- 9 people
- Sponsor
- Pfizer
Small Cell Lung Carcinoma
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with…
- Trial name
- IMpower133 (NCT02763579)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide
- Where
- 114 sites in United States, Australia and 19 more
- Volunteers
- 503 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00083161
- Testing
- cisplatin, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Gundersen Lutheran Health System